Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07043634 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects
A Phase 3 study of Bioavailability Heathy Volunteers, sponsored by Sarfez Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07043634: Completed Phase 3 study of Bioavailability Heathy Volunteers, sponsored by Sarfez Pharmaceuticals.
NCT07043634 is a Phase 3 study of Bioavailability Heathy Volunteers that has completed, run by Sarfez Pharmaceuticals. The registered enrollment target is 24 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07043634, a Phase 3 study of Bioavailability Heathy Volunteers, has completed, sponsored by Sarfez Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine comparative bioavailability of single dose of a fixed dose combination (FDC) of extended release Torsemide and Spironolactone given with or without food in healthy adult subjects.
Primary Outcome
Urine samples collected at each interval will be measured for the volume
Conditions Studied
Interventions
- COMBINATION_PRODUCT FDC (24 mg ER torsemide and 30 mg Spironolactone) without food
- COMBINATION_PRODUCT FDC (24 mg ER torsemide and 30 mg Spironolactone) with food
Study Locations (1)
Virginia
- Sarfez Pharmaceuticals - Vienna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-06-15 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 3 |
What the finished NCT07043634 record still lists
NCT07043634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Bioavailability Heathy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which FDC (24 mg ER torsemide and 30 mg Spironolactone) without food is the first listed.
NCT07043634 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT07043634 about?
NCT07043634 is a clinical study titled "A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects". This study will examine comparative bioavailability of single dose of a fixed dose combination (FDC) of extended release Torsemide and Spironolactone given with or without food in healthy adult subjects.
What is the current status of trial NCT07043634?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2025-06-15. Estimated completion is 2025-12-30.
What conditions does trial NCT07043634 study?
This clinical trial studies the following conditions: Bioavailability Heathy Volunteers.
What interventions are being tested in trial NCT07043634?
The interventions under investigation include: FDC (24 mg ER torsemide and 30 mg Spironolactone) without food (COMBINATION_PRODUCT), FDC (24 mg ER torsemide and 30 mg Spironolactone) with food (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07043634?
This trial is sponsored by Sarfez Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07043634 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07043634's enrollment target sits among peer trials
24 1943rd of 2000 higher than 49 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI